Fusion Proteins in the Fight against Colorectal Cancer: Assessing the Cytotoxic Potential of Recombinant Nisin-Arginine Deiminase Fusion Protein

Document Type : Original Research

Authors
1 Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran2Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
4 Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
Abstract
Background: A promising strategy in cancer therapy involves the production of fusion proteins, which entail the fusion of two distinct proteins. This study aimed to produce and assess the cytotoxic effects of the Nisin-arginine deiminase (ADI) fusion protein on the SW480 cell lines, a common model for studying colorectal cancer (CRC).

Materials & Methods: The designed Nisin-ADI gene fragment sequence was sent to Biomatik Company for synthesis in pET-28a vectors between SacI and HindIII restriction enzyme sites. Escherichia coli (E. coli) DH5α and BL21 were utilized for cloning and protein expression, respectively. The recombinant fusion protein expression was induced by Isopropyl ß-D-1-thiogalactopyranoside (IPTG) and purified using Ni2+-nitrilotriacetic acid (1) resin affinity chromatography. Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were conducted to analyze the purified protein. The cytotoxic effect of the purified recombinant fusion protein on SW480 and NIH3T3 cells, as a control, was evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay.

Findings: The results of this study showed that the fusion protein had a significant impact on the SW480 cell lines. The Half-maximal inhibitory concentration (IC50) of the fusion protein was 30 µg/mL, indicating that it effectively inhibited the growth of cancer cells. However, the fusion protein did not significantly affect the control group.

Conclusion: This study provides helpful insights into the potential application of recombinant Nisin-ADI fusion proteins as a potential treatment option for colorectal cancer. The potential for selective targeting of cancer cells is promising as normal cells are unaffected by this fusion protein.

Keywords

Subjects


1. Granados-Romero JJ, Valderrama-Treviño AI, Contreras-Flores EH, Barrera-Mera B, Herrera Enríquez M, Uriarte-Ruíz K, et al. Colorectal cancer: a review. Int J Res Med Sci. 2017;5(11):4667.
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023;73(1):17-48.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
4. Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates. 2019;47:100646.
5. Duong MT-Q, Qin Y, You S-H, Min J-J. Bacteria-cancer interactions: bacteria-based cancer therapy. Experimental & molecular medicine. 2019;51(12):1-15.
6. Rong L, Lei Q, Zhang X-Z. Engineering living bacteria for cancer therapy. ACS Applied Bio Materials. 2020;3(12):8136-45.
7. Thanjavur N, Sangubotla R, Lakshmi BA, Rayi R, Mekala CD, Reddy AS, et al. Evaluating the antimicrobial and apoptogenic properties of bacteriocin (nisin) produced by Lactococcus lactis. Process Biochemistry. 2022;122:76-86.
8. Thakker DP, Narayanan R. Arginine deiminase produced by lactic acid bacteria as a potent anticancer drug. Medical Oncology. 2023;40(6):1-13.
9. Hosseini SS, Goudarzi H, Ghalavand Z, Hajikhani B, Rafeieiatani Z, Hakemi-Vala M. Antiproliferative effects of cell wall, cytoplasmic extract of Lactococcus lactis and nisin through down-regulation of cyclin D1 on SW480 colorectal cancer cell line. Iranian Journal of Microbiology. 2020;12(5):424.
10. de Arauz LJ, Jozala AF, Mazzola PG, Penna TCV. Nisin biotechnological production and application: a review. Trends in Food Science & Technology. 2009;20(3-4):146-54.
11. Hosseini SS, Hajikhani B, Faghihloo E, Goudarzi H. Increased expression of caspase genes in colorectal cancer cell line by nisin. Archives of Clinical Infectious Diseases. 2020;15(2).
12. Ni Y, Schwaneberg U, Sun Z-H. Arginine deiminase, a potential antitumor drug. Cancer letters. 2008;261(1):1-11.
13. Funayama R, Taniguchi H, Mizuma M, Fujishima F, Kobayashi M, Ohnuma S, et al. Protein‐arginine deiminase 2 suppresses proliferation of colon cancer cells through protein citrullination. Cancer science. 2017;108(4):713-8.
14. Cheng F, Zhu L, Lue H, Bernhagen J, Schwaneberg U. Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas. Applied microbiology and biotechnology. 2015;99:1237-47.
15. Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nature methods. 2022;19(6):679-82.
16. Hull R. Colorectal Cancer Genetics, Incidence and Risk Factors: In Search for Targeted Therapies. Cancer management and research.12:9869-82.
17. Mattiuzzi C. Concise update on colorectal cancer epidemiology. Annals of Translational Medicine.7(21):609-.
18. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a review. Updates in surgery. 2016;68:7-11.
19. Numico G. Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer. Current Opinion in Oncology.27(4):351-7.
20. Abdelghani Z, Hourani N, Zaidan Z, Dbaibo G, Mrad M, Hage-Sleiman R. Therapeutic applications and biological activities of bacterial bioactive extracts. Archives of microbiology. 2021;203(8):4755-76.
21. Karpiński TM, Adamczak A. Anticancer activity of bacterial proteins and peptides. Pharmaceutics. 2018;10(2):54.
22. Baindara P, Mandal SM. Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics. Biochimie. 2020;177:164-89.
23. Löfblom J. Bacterial display in combinatorial protein engineering. Biotechnology journal. 2011;6(9):1115-29.
24. Yadav DK. An insight into fusion technology aiding efficient recombinant protein production for functional proteomics. Archives of Biochemistry and Biophysics.612:57-77.
25. Fathizadeh H, Saffari M, Esmaeili D, Moniri R, Kafil HS. Bacteriocins: New Potential Therapeutic Candidates in Cancer Therapy. Current molecular medicine. 2021;21(3):211-20.
26. Gharsallaoui A, Oulahal N, Joly C, Degraeve P. Nisin as a food preservative: part 1: physicochemical properties, antimicrobial activity, and main uses. Critical reviews in food science and nutrition. 2016;56(8):1262-74.
27. Ahmadi S, Ghollasi M, Hosseini HM. The apoptotic impact of nisin as a potent bacteriocin on the colon cancer cells. Microbial pathogenesis. 2017;111:193-7.
28. Zhang B. Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT- 29 cells. Microbial Cell Factories.15(1):102-.
29. Zhang Y. Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination. Cancer Letters.502:58-70.
30. Ts Y. A randomized phase II study of pegylated arginine deiminase (ADI-PEG 2 0) in Asian advanced hepatocellular carcinoma patients. British Journal of Cancer.103(7):954-60.
31. Liu D. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. Molecular Cancer.13(1):53-.
32. Berger S, Lowe P, Tesar M, editors. Fusion protein technologies for biopharmaceuticals: Applications and challenges: Editor Stefan R Schmidt. MAbs; 2015: Taylor & Francis.
33. Silver AB, Leonard EK, Gould JR, Spangler JB. Engineered antibody fusion proteins for targeted disease therapy. Trends in pharmacological sciences. 2021;42(12):1064-81.